This invention relates to the use of butyrate prodrugs derived from lactic acid for treating inflammatory bowel disease. The invention also relates to the use of those prodrugs for the treatment of a chemotherapy-induced mucocutaneous side effect in a patient. The invention further relates to the use of butyrate prodrugs for treating lung, colo-rectal or prostate cancer. And the invention also relates to the use of butyrate prodrugs to treat cystic fibrosis and to enhance the efficiency of gene therapy.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuing application of co-pending International patent application PCT/US98/04413, filed Mar. 10, 1998, which designated the United States.
